ArticleBMC complementary medicine and therapies2026
Synergistic anti-cancer activity of Artemisia vulgaris L. aqueous extract with cisplatin against A549 lung cancer cell line.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing resistance and adverse effects associated with conventional chemotherapeutic agents such as cisplatin have prompted the investigation of natural compounds that act synergistically with chemotherapy to combat cancer. This study investigates the cytotoxic effects of an aqueous extract of Artemisia vulgaris L. in conjunction with cisplatin on A549 human lung cancer cells. The research analyzes the phytochemical composition of the extract and its potential mechanisms of action by assessing apoptosis and autophagy. Cytotoxicity studies demonstrated a synergistic interaction between A. vulgaris and cisplatin. We utilized molecular docking to examine the interactions of the extract components with critical proteins involved in these processes.
methodsLiquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to characterize the phytochemicals in A. vulgaris. A549 cells were subjected to various concentrations of A. vulgaris L. aqueous extract, cisplatin, and their combination. We utilized the SRB assay to assess cell viability and the combination index (CI) analysis to evaluate the synergistic interaction between the two compounds. Molecular docking was performed for selected compounds against apoptotic and autophagic target proteins.
resultsThe combination treatment showed a greater cytotoxic effect than either treatment alone, suggesting a synergistic improvement of anticancer action through the induction of both apoptosis and autophagy. This was manifested by a significant decrease in the IC
conclusionThe results indicated that A. vulgaris L. may potentiate the anticancer effect of cisplatin, potentially allowing dose reduction and minimizing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.